AIM: The objective of the present study was to use pharmacokinetic-pharmacodynamic modelling to characterize the effects of chemotherapy on the granulopoietic system and to predict the absolute neutrophil counts (ANCs) for patients with chemotherapy-induced neutropenia treated with filgrastim and pegfilgrastim. METHODS: Data were extracted from 10 phase I-III studies conducted in 110 healthy adults, and 618 adult and 52 paediatric patients on chemotherapy following administration of filgrastim or pegfilgrastim. The structural model accounted for ANC dynamics and the effects of filgrastim and pegfilgrastim, chemotherapy and corticosteroids. The impact of neutrophils on drug disposition was based on a drug receptor-binding model that assumed quasi-equilibrium and stimulation of the production and maturation of neutrophils upon treatment. The chemotherapy and corticosteroid effects were represented by kinetic-pharmacodynamic-type models, where chemotherapy stimulated elimination of neutrophil precursors at the mitotic stage, and corticosteroids stimulated neutrophil production. RESULTS: The systemic half-lives of filgrastim (2.6 h) and pegfilgrastim (10.1 h) were as expected. The effective half-life of chemotherapy was 9.6 h, with a 2-day killing effect. The rate of receptor elimination from mitotic compartments exhibited extreme interindividual variability (% coefficient of variation >200), suggesting marked differences in sensitivity to chemotherapy effects on ANCs. The stimulatory effects of pegfilgrastim were significantly greater than those of filgrastim. Model qualification confirmed the predictive capability of this model. CONCLUSION: This qualified model simulates the time course of ANC in the absence or presence of chemotherapy and predicts nadir, time to nadir and time of recovery from different grades of neutropenia upon treatment with filgrastim and pegfilgrastim.
AIM: The objective of the present study was to use pharmacokinetic-pharmacodynamic modelling to characterize the effects of chemotherapy on the granulopoietic system and to predict the absolute neutrophil counts (ANCs) for patients with chemotherapy-induced neutropenia treated with filgrastim and pegfilgrastim. METHODS: Data were extracted from 10 phase I-III studies conducted in 110 healthy adults, and 618 adult and 52 paediatric patients on chemotherapy following administration of filgrastim or pegfilgrastim. The structural model accounted for ANC dynamics and the effects of filgrastim and pegfilgrastim, chemotherapy and corticosteroids. The impact of neutrophils on drug disposition was based on a drug receptor-binding model that assumed quasi-equilibrium and stimulation of the production and maturation of neutrophils upon treatment. The chemotherapy and corticosteroid effects were represented by kinetic-pharmacodynamic-type models, where chemotherapy stimulated elimination of neutrophil precursors at the mitotic stage, and corticosteroids stimulated neutrophil production. RESULTS: The systemic half-lives of filgrastim (2.6 h) and pegfilgrastim (10.1 h) were as expected. The effective half-life of chemotherapy was 9.6 h, with a 2-day killing effect. The rate of receptor elimination from mitotic compartments exhibited extreme interindividual variability (% coefficient of variation >200), suggesting marked differences in sensitivity to chemotherapy effects on ANCs. The stimulatory effects of pegfilgrastim were significantly greater than those of filgrastim. Model qualification confirmed the predictive capability of this model. CONCLUSION: This qualified model simulates the time course of ANC in the absence or presence of chemotherapy and predicts nadir, time to nadir and time of recovery from different grades of neutropenia upon treatment with filgrastim and pegfilgrastim.
Authors: Yow-Ming C Wang; Wojciech Krzyzanski; Sameer Doshi; Jim J Xiao; Juan Jose Pérez-Ruixo; Andrew T Chow Journal: AAPS J Date: 2010-10-21 Impact factor: 4.009
Authors: Charlotte Summers; Sara M Rankin; Alison M Condliffe; Nanak Singh; A Michael Peters; Edwin R Chilvers Journal: Trends Immunol Date: 2010-08 Impact factor: 16.687
Authors: Simon D Harding; Joanna L Sharman; Elena Faccenda; Chris Southan; Adam J Pawson; Sam Ireland; Alasdair J G Gray; Liam Bruce; Stephen P H Alexander; Stephen Anderton; Clare Bryant; Anthony P Davenport; Christian Doerig; Doriano Fabbro; Francesca Levi-Schaffer; Michael Spedding; Jamie A Davies Journal: Nucleic Acids Res Date: 2018-01-04 Impact factor: 16.971
Authors: Murad Melhem; Isabelle Delor; Juan Jose Pérez-Ruixo; John Harrold; Andrew Chow; Liviawati Wu; Philippe Jacqmin Journal: Br J Clin Pharmacol Date: 2018-02-20 Impact factor: 4.335
Authors: Matias F Martinez; Enzo Alveal; Tomas G Soto; Eva I Bustamante; Fernanda Ávila; Shrikant I Bangdiwala; Ivonne Flores; Claudia Benavides; Ricardo Morales; Nelson M Varela; Luis A Quiñones Journal: Pharmgenomics Pers Med Date: 2020-08-19
Authors: John Harrold; Per Olsson Gisleskog; Isabelle Delor; Philippe Jacqmin; Juan Jose Perez-Ruixo; Adimoolam Narayanan; Sameer Doshi; Andrew Chow; Bing-Bing Yang; Murad Melhem Journal: Pharm Res Date: 2020-05-21 Impact factor: 4.200
Authors: Anne Bellon; Jessie Wang; Andrej Skerjanec; Maria Velinova; Daniel Dickerson; Ahad Sabet; Ly Ngo; Terry O'Reilly; Charles Tomek; Steven Schussler; Stefanie Schier-Mumzhiu; Sreekanth Gattu; Sven D Koch; Celine Schelcher; Miryana Dobreva; Anca Boldea; Roumen Nakov; Gordon P Otto Journal: Br J Clin Pharmacol Date: 2020-02-21 Impact factor: 4.335
Authors: Anna Kondic; Dean Bottino; John Harrold; Jeffrey D Kearns; C J Musante; Aleksandrs Odinecs; Saroja Ramanujan; Jangir Selimkhanov; Birgit Schoeberl Journal: Front Pharmacol Date: 2022-04-12 Impact factor: 5.988
Authors: Yu Kyoung Cho; Donald J Irby; Junan Li; Douglas W Sborov; Diane R Mould; Mohamed Badawi; Anees Dauki; Misty Lamprecht; Ashley E Rosko; Soledad Fernandez; Erinn M Hade; Craig C Hofmeister; Ming Poi; Mitch A Phelps Journal: CPT Pharmacometrics Syst Pharmacol Date: 2018-10-20